You searched for Breast cancer - Page 3 of 26

News and Trends 15 Jan 2018

The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead

The UK big pharma company’s Lynparza will be for women with advanced breast cancer that is specifically caused by mutations in the BRCA gene. Global pharma giant AstraZeneca focuses on the development of drugs for cancer, cardiovascular and respiratory diseases. The company, which is working on a number of small molecules and biologics for a […]

January 15, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […]

October 19, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 May 2017

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

Tumor cells that survive chemotherapy and drive breast cancer relapse may provide drug targets for potential treatments to reduce the recurrence. In mice, some breast tumor cells can survive chemotherapy and drive the recurrence of tumor, found a team of researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and in Monterotondo, Italy; […]

May 25, 2017 - 3 minutesmins - By External Contributor

Transgene Pexa Vec Oncolytic Virus Vaccine

News and Trends 13 Apr 2017

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

qiagen therawis diagnostics chemotherapy tnbc

News and Trends 26 May 2016

Qiagen partners up for Novel Diagnostic against Breast Cancer

Qiagen is partnering up with Therawis to develop a diagnostic test to predict how effective an aggressive chemotherapy will be in patients with high risk breast cancer. A giant in molecular diagnostics, Qiagen is now working in a new diagnostic test that could help guide the treatment of breast cancer. Now, Qiagen has partnered with […]

May 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

agendia mammaprint breast cancer metastasis risk

News and Trends 2 May 2016

Genetic Diagnostic can cut number of Breast Cancer Patients needing Chemo in Half

Agendia’s shows remarkable clinical results for its genomic assay (MammaPrint) allowed 48% of early-stage breast cancer patients to be spared from chemotherapy. Agendia started out in 2003 as a spin-off from the Netherlands Cancer Institute to commercialize diagnostic tools for cancer. Its first product was MammaPrint, which uses DNA microarray technology to test the activity 70 genes that […]

May 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

berlin myelo therapeutics chemo cancer drug trial

News and Trends 15 Dec 2015

Berlin Biotech Breakthrough: Myelo is Only 3 Years old and Already Starting a Phase II Trial for Breast Cancer!

Myelo Therapeutics in Berlin (Germany) has been approved for a phase II trial for its Chemo-induced Neutropenia therapy for Breast cancer after completing a successful series B financing round. A reduced level of neutrophils (a type of leukocyte) is called neutropenia. It can leave a patient vulnerable to infection and to developing febrile neutropenia, a […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

In Depth 22 Feb 2024

TIL therapies: the impact on cancer research

The approval of the first-ever TIL therapy has made it possible to treat hundreds of thousands of people affected by skin cancer in the US.

February 22, 2024 - 10 minutesmins - By Roohi Mariam Peter

In Depth 5 Feb 2024

Future of cancer treatment: what will therapy look like in 2034?

From groundbreaking immunotherapies to AI diagnostics and new vaccines, explore the innovations shaping the future of cancer treatment.

February 5, 2024 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 1 Dec 2023

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]

December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter

In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]

November 23, 2023 - 5 minutesmins - By Jules Adam

ODS Paris In vitro 386 Antoine Martel Photographe

Chronic inflammation and cancer: how can preclinical models revolutionize our understanding?

In most cases, chronic inflammation is known to lead to cancer, however, the mechanisms behind this are not fully understood. Preclinical models in immuno-oncology are the first step towards a better understanding of cancer mechanisms, improved treatments and prevention of cancer caused by inflammation. Inflammation is the immune system’s natural response to bacterial, viral, and […]

October 24, 2023 - 7 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Breast cancer

The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

Qiagen partners up for Novel Diagnostic against Breast Cancer

Genetic Diagnostic can cut number of Breast Cancer Patients needing Chemo in Half

Berlin Biotech Breakthrough: Myelo is Only 3 Years old and Already Starting a Phase II Trial for Breast Cancer!

TIL therapies: the impact on cancer research

Future of cancer treatment: what will therapy look like in 2034?

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Chronic inflammation and cancer: how can preclinical models revolutionize our understanding?

Subscribe to our newsletter to get the latest biotech news!